Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Investigating incidence of RAS/RAF and PIK3CA alterations in HER2-amplified colorectal cancer: a comprehensive analysis.

The oncologist - 4 Jul 2025

Cheng Svea, Gomez Cyndi Gonzales, Ferrell Morgan, Giza Richard, Syed Masood Pasha, Magge Tara, Gorantla Vikram, Hsieh Ronan W, Bao Riyue, Singhi Aatur, Saeed Anwaar, Sahin Ibrahim Halil

Abstract excerpt

BACKGROUND: Amplification of human epidermal growth factor receptor-2 (HER2) can be targeted with HER2-directed combination therapies for patients with colorectal cancer (CRC). Evolving data from clinical trials suggest mutations in KRAS and PIK3CA, downstream effectors of HER2, may confer resistance to HER2 blockade. However, the true incidence of these alterations in HER2-amplified CRC is largely unknown. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Gene Amplification

Share to Incidence

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to raf Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 40742050
DOI: 10.1093/oncolo/oyaf158
PMCID: PMC12311930

Genes

PIK3CA
KRAS
BRAF
MAPK1
MAPK3
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Investigating incidence of RAS/RAF and PIK3CA alterations in HER2-amplified colorectal cancer: a comprehensive analysis.PMID 40742050Read ↗

Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma.Semantic proximity Read ↗

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.Semantic proximity Read ↗

Genomic landscape and clinical characteristics of ERBB2/HER2-mutated colorectal cancers.Semantic proximity Read ↗

HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic SchemesSemantic proximity Read ↗

Exploring the Relationship Between KRAS, NRAS, and BRAF Mutations and Clinical Characteristics in Iranian Colorectal Cancer Patients.Semantic proximity Read ↗

KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics.Semantic proximity Read ↗

RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification.Semantic proximity Read ↗

Comprehensive genomic profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancerSemantic proximity Read ↗

Next-Generation Sequencing-Based Detection of KRAS G12D Variants in Colorectal Cancer: A Retrospective Cohort Study.Semantic proximity Read ↗

Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.Semantic proximity Read ↗

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.Semantic proximity Read ↗

[Relationship between KRAS gene mutation sites and clinical characteristics in colorectal cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.